• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of and finding treatments for complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

Grant to Hemispherx for Ampligen and Alferon

Rita

Senior Member
Messages
235
Nov. 10, 2010, 8:00 a.m. EST
Hemispherx Biopharma Receives Therapeutic Discovery Project Grant From
U.S. Department of Treasury
Covers Therapeutic Applications of Two Technology Platforms

PHILADELPHIA, Nov 10, 2010 (GlobeNewswire via COMTEX) -- Hemispherx
Biopharma, Inc. /quotes/comstock/14*!heb/quotes/nls/heb (HEB 0.50,
-.00, -0.44%) announced today grant awards totaling $488,958 from the
U.S. Department of Treasury in support of its Ampligen(R) and
Alferon(R) development programs. These awards were approved by the
Internal Revenue Service (IRS), in conjunction with the Department of
Heath and Human Services (DHHS), under the Qualifying Therapeutic
Discovery Project Program, established under the Patient Protection
and Affordable Care Act of 2010 for projects that showed significant
potential to produce new and cost-saving therapies, support jobs and
increase U.S. competitiveness. The amounts granted for these two
Hemispherx projects were for the maximum per-project amount set by the
IRS based on the limited amount of funds allocated for the program.

The Hemispherx Alferon(R) program grant application was based on the
potential to show Alferon N Injection(R), an FDA-approved treatment
for refractory HPV, and Alferon(R) LDO (low dose oral), an
experimental formulation, to be an efficacious and inexpensive
preventative or treatment for seasonal and pandemic flu.

The Hemispherx Ampligen(R) grant application was based on the
continuing development of Ampligen(R) (an experimental therapeutic
with broad spectrum antiviral properties) in clinical programs in
Chronic Fatigue Syndrome, (CFS) and as an adjuvant for seasonal /
pandemic influenza vaccines and cancer immunotherapy.
 

mojoey

Senior Member
Messages
1,213
We talked about this on another thread. This is old news from 2009. Check this out: http://www.irs.gov/businesses/small/...229011,00.html

Add up the amounts of the grants awarded to hemispherx in 2009 and you get $488958 which is the amount they announced in the article.

Seeing as hemispherx is the source of the PR release, is it then true that they lied or at least were being misleading by announcing old news as new news? In either case I wouldn't be at all surprised.
 

dannybex

Senior Member
Messages
3,561
Location
Seattle
Seeing as hemispherx is the source of the PR release, is it then true that they lied or at least were being misleading by announcing old news as new news?

They have a long history of doing exactly that. Unfortunately...

I don't understand how they can let the CEO get away with these things, repeatedly. A great example of his doublespeak occurred last year on several occasions during the months leading up to the FDA's ruling:

http://www.thestreet.com/story/10620979/hemispherx-cops-to-ampligen-fda-delay.html

"Monday's statement was likely crafted by Hemispherx's lawyers as a way to help CEO Bill Carter wiggle out of public statements he made in May and June claiming the Ampligen application to the U.S. Food and Drug Administration to be complete. Carter insisted regulators weren't asking for any additional information on Ampligen.

Carter's made these statements both before and immediately after the FDA approval decision date for Ampligen on May 25, which came and went without any word from the agency. We now know that Carter's statements were demonstrably false. The FDA application for Ampligen was not complete because several items were outstanding, the company now states. These included FDA requests for data on Ampligen's safety both in humans and animals. The FDA also required additional information about Ampligen's manufacturing."

Sigh.
 

eric_s

Senior Member
Messages
1,925
Location
Switzerland/Spain (Valencia)
We talked about this on another thread. This is old news from 2009. Check this out: http://www.irs.gov/businesses/small/...229011,00.html

Add up the amounts of the grants awarded to hemispherx in 2009 and you get $488958 which is the amount they announced in the article.

Seeing as hemispherx is the source of the PR release, is it then true that they lied or at least were being misleading by announcing old news as new news? In either case I wouldn't be at all surprised.
Are you sure?

It says
These awards were approved by the
Internal Revenue Service (IRS), in conjunction with the Department of
Heath and Human Services (DHHS), under the Qualifying Therapeutic
Discovery Project Program, established under the Patient Protection
and Affordable Care Act of 2010 for projects that showed significant
potential to produce new and cost-saving therapies, support jobs and
increase U.S. competitiveness.
How could it be old grants if the program was established under a law of 2010?

Either way, if there were grants in 2009 too, it does not indicate a shift in policy. Too bad. But at least they get some money, which should be a good thing.

If they only were a bit more serious, as they seem to have something that's at least more helpful than most of the rest...